Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

@article{Dormandy2005SecondaryPO,
  title={Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial},
  author={J. Dormandy and B. Charbonnel and D. Eckland and E. Erdmann and O. B. O. E. investigators},
  journal={The Lancet},
  year={2005},
  volume={366},
  pages={1279-1289}
}
BACKGROUND Patients with type 2 diabetes are at high risk of fatal and non-fatal myocardial infarction and stroke. There is indirect evidence that agonists of peroxisome proliferator-activated receptor gamma (PPAR gamma) could reduce macrovascular complications. Our aim, therefore, was to ascertain whether pioglitazone reduces macrovascular morbidity and mortality in high-risk patients with type 2 diabetes. METHODS We did a prospective, randomised controlled trial in 5238 patients with type 2… Expand
3,662 Citations

Paper Mentions

Interventional Clinical Trial
Epidemiologic, social and economic burdens of type 2 diabetes mellitus (T2DM) keep rising worldwide. Implementation of T2DM preventive trategies is lagging behind. Metabolic surgery… Expand
ConditionsNewly Diagnosed Type 2 Diabetes
InterventionDrug
Interventional Clinical Trial
The purpose of this study is to determine whether pioglitazone, once daily (QD), can delay the time to death, heart attack, acute coronary syndrome, heart bypass surgery, stroke, leg… Expand
ConditionsDiabetes Mellitus
InterventionDrug
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
...
1
2
3
4
...